2025-04-05 - Analysis Report
## Eli Lilly and Co. (LLY) Stock Report

**0. Executive Summary:**

Eli Lilly and Co. (LLY) is a leading pharmaceutical company.  This report analyzes LLY's performance based on provided financial data, comparing it to the S&P 500 (VOO) and assessing its risk and potential return.

**1. Performance Comparison with S&P 500:**

LLY's cumulative return (282.31%) significantly outperforms the S&P 500's cumulative return (71.02%). The difference is 211.3%, placing it at the 71st percentile of historical performance relative to the S&P 500 based on the provided range.  This suggests LLY has historically generated substantially higher returns than the broader market.

**Alpha and Beta Analysis:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 10.0% | 55.6% | -20.0% | 0.1 | 67.7 |
| 2016-2018  | 38.0% | 58.6% | 21.0% | -0.2 | 95.1 |
| 2017-2019  | 49.0% | 58.6% | 20.0% | 0.5 | 110.4 |
| 2018-2020  | 63.0% | 58.6% | 33.0% | 0.2 | 144.7 |
| 2019-2021  | 119.0% | 11.1% | 44.0% | 0.3 | 240.3 |
| 2020-2022  | 113.0% | 63.0% | 92.0% | 0.3 | 322.6 |
| 2021-2023  | 133.0% | 63.0% | 105.0% | 0.3 | 519.2 |
| 2022-2024  | 155.0% | 67.4% | 139.0% | 0.3 | 692.0 |
| 2023-2025  | 121.0% | 76.9% | 118.0% | 0.3 | 662.9 |

The data shows significant variation in CAGR and Alpha across different periods. While Beta generally remains around 0.3, indicating moderate sensitivity to market movements, Alpha fluctuates, reflecting periods of outperformance and underperformance relative to the market.  The high CAGRs in recent years suggest strong growth.  Note that the Alpha values seem unusually high and may warrant further investigation into the methodology used for their calculation.

**2. Recent Price Movement:**

* **Closing Price:** $738.21
* **Last Day Change:** -$6.45 (from $789.09)
* **5-Day Moving Average:** $795.33
* **20-Day Moving Average:** $821.00
* **60-Day Moving Average:** $832.38

The stock price is currently below all three moving averages, indicating a possible bearish trend. The significant single-day drop suggests a potential catalyst for the decline.

**3. Technical Indicators:**

* **Market Risk Indicator (MRI):** 0.4693 (High Risk)
* **RSI:** 29.95 (Oversold)
* **PPO:** -1.01 (Bearish)
* **20-Day Relative Divergence Change:** +1.7 (Short-term upward trend)

The indicators suggest a bearish outlook. The RSI is in oversold territory, which could indicate a potential bounce, but the negative PPO and high MRI suggest caution.  The recent price drop indicates a potentially significant event impacting the price.

**Expected Return:** 70.1%  This is a long-term (2+ years) expected excess return compared to the S&P 500, assuming continued outperformance.  However, given the recent price drop and indicators, achieving this expected return is uncertain and depends on various market factors.

**4. Recent Earnings Analysis:**

| Date       | EPS   | Revenue       |
|------------|-------|---------------|
| 2024-10-30 | $1.08 | $11.44B       |
| 2024-08-08 | $3.29 | $11.30B       |
| 2024-04-30 | $2.49 | $8.77B        |
| 2023-11-02 | -$0.06| $9.50B        |
| 2024-10-30 | -$0.06| $9.50B        |

There's a duplicate entry for October 30th, 2024.  Revenue appears relatively stable, but EPS shows significant variability, with a notable loss in Q4 2023 and Q4 2024 (duplicated entry).  Further investigation is needed to understand the causes of these EPS fluctuations.

**5. Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue     | Profit Margin |
|---------|-------------|---------------|
| 2024-12-31 | $13.53B    | 82.24%        |
| 2024-09-30 | $11.44B    | 81.02%        |
| 2024-06-30 | $11.30B    | 80.80%        |
| 2024-03-31 | $8.77B     | 80.91%        |
| 2023-12-31 | $9.35B     | 80.88%        |

Revenue shows a clear upward trend, and profit margins remain consistently high, indicating strong financial health.

**Capital and Profitability:**

| Quarter | Equity      | ROE           |
|---------|-------------|---------------|
| 2024-12-31 | $14.19B    | 31.07%        |
| 2024-09-30 | $14.24B    | 6.81%         |
| 2024-06-30 | $13.56B    | 21.88%        |
| 2024-03-31 | $12.81B    | 17.51%        |
| 2023-12-31 | $10.77B    | 20.33%        |

Equity generally increases, but ROE shows significant fluctuations.  This warrants further analysis to understand the drivers behind the changes in ROE.


**6. Overall Analysis:**

LLY has historically demonstrated strong performance relative to the S&P 500, with significantly higher cumulative returns.  However, the recent price decline and bearish technical indicators raise concerns.  While the company displays strong revenue and generally high profit margins, the fluctuating EPS and ROE require further investigation.  The high expected return is predicated on continued outperformance but is subject to significant uncertainty given the current market conditions and recent price movement.  A deeper dive into the causes of the recent price drop and the variability in EPS and ROE is crucial before making any investment decisions.  Careful consideration of the risks associated with high-growth pharmaceutical stocks is also recommended.
